LaFleur & Godfrey LLC Sells 4,876 Shares of Zoetis Inc. $ZTS

LaFleur & Godfrey LLC reduced its holdings in Zoetis Inc. (NYSE:ZTS) by 24.9% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 14,674 shares of the company’s stock after selling 4,876 shares during the quarter. LaFleur & Godfrey LLC’s holdings in Zoetis were worth $1,846,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. CIBC Asset Management Inc grew its stake in Zoetis by 4.3% in the 3rd quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock worth $36,745,000 after buying an additional 10,434 shares in the last quarter. Nordea Investment Management AB increased its holdings in shares of Zoetis by 79.2% in the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock worth $622,222,000 after buying an additional 2,179,578 shares during the last quarter. Seilern Investment Management Ltd raised its position in shares of Zoetis by 361.2% during the 4th quarter. Seilern Investment Management Ltd now owns 333,465 shares of the company’s stock valued at $41,957,000 after buying an additional 261,155 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of Zoetis by 134.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,631,619 shares of the company’s stock worth $205,290,000 after acquiring an additional 935,432 shares during the last quarter. Finally, Mitsubishi UFJ Trust & Banking Corp lifted its holdings in shares of Zoetis by 6.5% during the 3rd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company’s stock worth $43,235,000 after acquiring an additional 18,040 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. BTIG Research reissued a “buy” rating and issued a $160.00 target price on shares of Zoetis in a research note on Thursday, February 26th. William Blair reaffirmed an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Piper Sandler reiterated a “neutral” rating and issued a $135.00 price objective (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Citigroup began coverage on Zoetis in a research report on Wednesday, April 15th. They set a “buy” rating and a $145.00 price objective on the stock. Finally, Bank of America raised their price objective on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a report on Friday, February 13th. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $151.75.

Zoetis Stock Down 0.1%

Shares of NYSE:ZTS opened at $112.60 on Wednesday. The stock has a market capitalization of $47.36 billion, a P/E ratio of 18.70, a price-to-earnings-growth ratio of 1.73 and a beta of 0.87. The stock’s 50-day moving average price is $119.61 and its 200-day moving average price is $124.33. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. Zoetis Inc. has a 12-month low of $111.27 and a 12-month high of $172.23.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. The company had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.Zoetis’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities analysts anticipate that Zoetis Inc. will post 7.01 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.9%. Zoetis’s dividend payout ratio (DPR) is currently 35.22%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.